Correlation between p38 mitogen-activated protein kinase and human telomerase reverse transcriptase in sarcomas

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Matsuo, Toshihiro ^a,b   Shimose, Shoji ^b   Kubo, Tadahiko ^b   Fujimori, Jun ^b   Yasunaga, Yuji ^b   Sugita, Takashi ^a   Ochi, Mitsuo ^b  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

human telomerase reverse transcriptase; liposarcoma; malignant fibrous histiocytoma; p38 mitogen activated protein kinase

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HISTIOCYTOMA; HUMAN; HUMAN TISSUE; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; SOFT TISSUE; CANCER STAGING; GENE EXPRESSION REGULATION; GENETICS; MALIGNANT FIBROUS HISTIOCYTOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROGNOSIS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84855771031     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-5     Document Type: Article

References (39)

1. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
2. de Lange T: Activation of telomerase in a human tumor. Proc Natl Acad Sci USA 1994, 91:2882-2885.
3. Hiyama E, Yokoyama T, Tatsumoto N, Hiyama K, Imamura Y, Murakami Y, Kodama T, Piatyszek MA, Shay JW, Matsuura Y: Telomerase activity in gastric cancer. Cancer Res 1995, 55:3258-3262.
4. Tatsumoto N, Hiyama E, Murakami Y, Imamura Y, Shay JW, Matsuura Y, Yokoyama T: High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res 2000, 6:2696-2701. (Pubitemid 30482106)
5. Hiyama E, Hiyama K: Clinical utility of telomerase in cancer. Oncogene 2002, 21:643-649. (Pubitemid 34146266)
6. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, Bodnar AG, Lichtsteiner S, Kim NW, Trager JB, Taylor RD, Carlos R, Andrews WH, Wright WE, Shay JW, Harley CB, Morin GB: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997, 17:498-502. (Pubitemid 27518407)
7. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Tahara E, Ide T, Ishikawa F: Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998, 18:65-68. (Pubitemid 28027882)
8. Schneider-Stock R, Jaeger V, Rys J, Epplen JT, Roessner A: High telomerase activity and high HTRT mRNA expression differentiate pure myxoid and myxoid/round-cell liposarcomas. Int J Cancer 2000, 89:63-68. (Pubitemid 30078751)
9. Tomoda R, Seto M, Tsumuki H, Iida K, Yamazaki T, Sonoda J, Matsumine A, Uchida A: Telomerase activity and human telomerase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumors. Cancer 2002, 95:1127-1133. (Pubitemid 34925366)
10. Schneider-Stock R, Boltze C, Jäger V, Epplen J, Landt O, Peters B, Rys J, Roessner A: Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours. J Pathol 2003, 199:517-525. (Pubitemid 36416558)
11. Ohali A, Avigad S, Cohen IJ, Meller I, Kollender Y, Issakov J, Gelernter I, Goshen Y, Yaniv I, Zaizov R: Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors. J Clin Oncol 2003, 21:3836-3843. (Pubitemid 46606239)
12. Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS: Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol 2004, 22:3790-3797. (Pubitemid 41095220)
13. Fuchs B, Inwards C, Scully SP, Janknecht R: hTERT Is highly expressed in Ewing's sarcoma and activated by EWS-ETS oncoproteins. Clin Orthop Relat Res 2004, 426:64-68. (Pubitemid 39167109)
14. Sabah M, Cummins R, Leader M, Kay E: Immunohistochemical detection of hTERT protein in soft tissue sarcomas: correlation with tumor grade. Appl Immunohistochem Mol Morphol 2006, 14:198-202. (Pubitemid 43941185)
15. Ambrosino C, Nebreda AR: Cell cycle regulation by p38 MAP kinases. Biol Cell 2001, 93:47-51. (Pubitemid 33040859)
16. Bradham C, McClay DR: p38 MAPK in development and cancer. Cell Cycle 2006, 5:824-828. (Pubitemid 44145574)
17. Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA: p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 2009, 15:369-379.
18. Wang Z, Kyo S, Takakura M, Tanaka M, Yatabe N, Maida Y, Fujiwara M, Hayakawa J, Ohmichi M, Koike K, Inoue M: Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res 2000, 60:5376-5381.
19. Alfonso-De Matte MY, Yang H, Evans MS, Cheng JQ, Kruk PA: Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells. Cancer Res 2002, 62:4575-4578.
20. Maida Y, Kyo S, Kanaya T, Wang Z, Yatabe N, Tanaka M, Nakamura M, Ohmichi M, Gotoh N, Murakami S, Inoue M: Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene 2002, 21:4071-4079. (Pubitemid 34712874)
21. Goueli BS, Janknecht R: Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol 2004, 24:25-35. (Pubitemid 38010032)
22. Takakura M, Kyo S, Inoue M, Wright WE, Shay JW: Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells. Mol Cell Biol 2005, 25:8037-8043. (Pubitemid 41262997)
23. Matsuo T, Shay JW, Wright WE, Hiyama E, Shimose S, Kubo T, Sugita T, Yasunaga Y, Ochi M: Telomere-maintenance mechanisms in soft-tissue malignant fibrous histiocytomas. J Bone Joint Surg Am 2009, 91:928-937.
24. Matsuo T, Shimose S, Kubo T, Fujimori J, Yasunaga Y, Ochi M: Alternative lengthening of telomeres as a prognostic factor in malignant fibrous histiocytomas of bone. Anticancer Res 2010, 30:4959-4962.
25. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR: Telomerase catalytic subunit homologs from fission yeast and human. Science 1997, 277:955-959. (Pubitemid 27366681)
26. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997, 90:785-795. (Pubitemid 27357969)
27. Yan P, Benhattar J, Coindre JM, Guillou L: Telomerase activity and hTERT mRNA expression can be heterogeneous and does not correlate with telomere length in soft tissue sarcomas. Int J Cancer 2002, 98:851-856. (Pubitemid 34286680)
28. Yan P, Coindre JM, Benhattar J, Bosman FT, Guillou L: Telomerase activity and human telomerase reverse transcriptase mRNA expression in soft tissue tumors: correlation with grade, histology, and proliferative activity. Cancer Res 1999, 59:3166-3170. (Pubitemid 29316017)
29. Matsuo T, Shimose S, Kubo T, Fujimori J, Yasunaga Y, Ochi M: Telomeres and telomerase in sarcomas. Anticancer Res 2009, 29:3833-3836.
30. Yang J, Yu Y, Duerksen-Hughes PJ: Protein kinases and their involvement in the cellular responses to genotoxic stress. Mutat Res 2003, 543:31-58. (Pubitemid 36054177)
31. Dwyer J, Li H, Xu D, Liu JP: Transcriptional regulation of telomerase activity: roles of the the Ets transcription factor family. Ann N Y Acad Sci 2007, 1114:36-47. (Pubitemid 350070389)
32. Goueli BS, Janknecht R: Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor. Oncogene 2003, 22:8042-8047. (Pubitemid 37175868)
33. Nebreda AR, Porras A: p38 MAP kinases: beyond the stress response. Trends Biochem Sci 2000, 25:257-260. (Pubitemid 30333380)
34. Ono K, Han J: The p38 signal transduction pathway: activation and function. Cell Signal 2000, 12:1-13. (Pubitemid 30017963)
35. Neve RM, Holbro T, Hynes NE: Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 2002, 21:4567-4576. (Pubitemid 34785733)
36. Recio JA, Merlino G: Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 2002, 21:1000-1008. (Pubitemid 34174512)
37. Pomérance M, Quillard J, Chantoux F, Young J, Blondeau JP: High-level expression, activation, and subcellular localization of p38-MAP kinase in thyroid neoplasms. J Pathol 2006, 209:298-306. (Pubitemid 43997738)
38. Myatt SS, Redfern CP, Burchill SA: p38MAPK-Dependent sensitivity of Ewing's sarcoma family of tumors to fenretinide-induced cell death. Clin Cancer Res 2005, 11:3136-3148. (Pubitemid 40525221)
39. Halawani D, Mondeh R, Stanton LA, Beier F: p38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation. Oncogene 2004, 23:3726-3731. (Pubitemid 38658441)